Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 41kWORD 10k
25 February 2022
E-000804/2022/rev.1
Question for written answer  E-000804/2022/rev.1
to the Commission
Rule 138
João Pimenta Lopes (The Left)
 Answer in writing 
 Subject: Vaccine prices negotiated by the Commission

An article by Investigate Europe(1) has exposed the huge discrepancy between the estimated cost of producing the COVID-19 vaccines, the initially negotiated price and the current price: Pfizer/BioNTech, estimated production cost = USD 1.18, initially negotiated price per dose = USD 18.2, current price = USD 22.86; Moderna, estimated production cost = USD 2.85, initially negotiated price per dose = USD 22.4, current price = USD 25.40. The negotiating process lacked transparency throughout.

According to the article, the difference between the estimated costs and the amounts actually paid adds up to approximately EUR 31 billion, which paints a clear picture of the interests and motives of these profit-hungry multinationals. Against this background, it is even harder to comprehend the curbs placed on diversifying the vaccine portfolio, as well as the delay in assessing and approving other vaccines recognised by the World Health Organization (WHO) and in waiving patents.

In view of the above:

1. Can the Commission confirm the stated differences between the estimated costs of production, the initially contracted prices and those actually paid for these vaccines?

2. What impact will this evolution have on the EU budget and which items will cover this difference?

3. What are the reasons for the delay in approving WHO-recognised vaccines and the continued opposition to waiving patents?

(1)shorturl.at/bisS7
Original language of question: PT
Last updated: 16 March 2022Legal notice - Privacy policy